Skip to main content

Charles S. Berkman

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and earnings-call appearances connecting this person to public companies.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 OmniAb, Inc. (OABI) $503,528 $1,624,425
2024 OmniAb, Inc. (OABI) $494,479 $1,690,109
2023 OmniAb, Inc. (OABI) $485,576 $1,336,498
2022 Ligand Pharmaceuticals Inc (LGND) $396,920 $2,433,437
2022 OmniAb, Inc. (OABI) $476,393 $4,080,569
2021 Ligand Pharmaceuticals Inc (LGND) $451,682 $2,980,948
2021 OmniAb, Inc. (OABI) $451,682 $2,980,948
2020 Ligand Pharmaceuticals Inc (LGND) $441,917 $1,944,852
2019 Ligand Pharmaceuticals Inc (LGND) $427,620 $2,027,167
2018 Ligand Pharmaceuticals Inc (LGND) $402,500 $1,743,579
2017 Ligand Pharmaceuticals Inc (LGND) $362,812 $1,498,819

Recent activity

No earnings-call appearances or filed executive changes recorded yet.